Kidney transplant recipients need to take several immunosuppressive drugs following surgery to prevent rejection. However, these drugs can cause side effects which compromise long-term survival for both patients and grafted kidneys.
Cordyceps sinensis (Cordyceps) is used in traditional Chinese medicine settings. Cordyceps is thought to suppress organ rejection, reduce immunosuppressive drug use, and protect patients from drug-related side effects. However, because Cordyceps use is limited beyond settings that routinely treat people using traditional Chinese medicine, its benefits and harms are unclear.
We evaluated the use of Cordyceps following kidney transplantation to assess its safety, benefits and harms. We searched the literature published to September 2015 and found 156 records. Of these, 131 were from Chinese language databases and 25 from non-Chinese language sources. After assessment, we included five studies (six reports) that presented data from 447 adult patients who received Cordyceps treatment following kidney transplantation in China. Overall, we found that reporting and study designs were significantly flawed and may have overestimated benefits and underestimated harms.
Cordyceps was compared with azathioprine (an immunosuppressive drug). We found no significant differences between treatments in terms of patient or kidney survival, or organ rejection. We found some improvement in kidney function, anaemia, leucopenia, liver function and incidence of infection among people who received Cordyceps.
We also analysed Cordyceps in combination with low dose cyclosporin A (CsA, another immunosuppressive drug) versus standard dose CsA. We found no significant differences in patient or kidney survival, organ rejection, or kidney function between treatments. Cordyceps treatment was reported to lead to a reduction in CsA dose, improved rates of lung infection, albumin and uric acid levels in blood. Cordyceps also appeared to offer protective effects against kidney and liver damage that can occur with use of CsA; however this improvement may also have been due to the lower CsA dose.
Our review was limited by the few included studies with small numbers of participants that investigated Cordyceps for kidney transplant recipients. Effects of therapies were observed for very short periods which significantly limited the robustness of reported outcomes. Larger and more robust randomised studies that assess the benefits and harms of Cordyceps for people following kidney transplantation are needed to better inform clinical practice.
阅读完整摘要
Kidney transplantation is the treatment of choice for patients with end-stage kidney disease (ESKD). Rising ESKD prevalence has substantially increased numbers of kidney transplants performed. Maintenance immunosuppression is long-term treatment to prevent acute rejection and deterioration of graft function. Although immunosuppressive treatment using drugs such as calcineurin inhibitors (CNIs, such as cyclosporin A (CsA) or tacrolimus) reduce acute rejection rates, long-term allograft survival rates are not significantly enhanced. CNI-related adverse effects contribute to reduced quality of life among kidney transplant recipients. Adjuvant immunosuppressive therapies that could offer a synergetic immunosuppressive effect, while minimising toxicity and reducing side effects, have been explored recently.
Cordyceps sinensis, (Cordyceps) a traditional Chinese medicine, is used as an adjuvant immunosuppressive agent in maintenance treatment for kidney transplantation recipients in China, but there is no consensus about its use as an adjuvant immunosuppressive treatment for kidney transplantation recipients.
研究目的
This review aimed to evaluate the benefits and potential adverse effects of Cordyceps as an adjuvant immunosuppressive treatment for kidney transplant recipients.
检索策略
We searched the Cochrane Kidney and Transplant Specialised Register through contact with the Trials Search Co-ordinator to 7 September 2015 using search terms relevant to this review. We also searched Chinese language databases and other resources.
纳入排除标准
We included all randomised controlled trials (RCTs) and quasi-RCTs evaluating the benefits and potential side effects of Cordyceps sinensis for kidney transplant recipients, irrespective of blinding or publication language. An inclusion criterion was that baseline immunosuppressive therapy must be the same in all study arms.
资料收集与分析
Two authors extracted data. We derived risk ratios (RR) for dichotomous data and mean differences (MD) for continuous data with 95% confidence intervals (CI).
主要结果
Our review included five studies (six reports; 447 participants) that assessed Cordyceps. Limited reporting of study methods and data meant that all included studies were assessed as having unclear risks of bias. The studies investigated Cordyceps compared with azathioprine (AZA) (4 studies, 265 participants) and Cordyceps plus low dose CsA versus standard dose CsA (1 study, 182 participants).
Compared with AZA, Cordyceps showed no significant difference in graft or patient survival, but improved graft function and may reduce acute rejection episodes. Anaemia, leucopenia, and liver function improved, and incidence of infection may also be reduced.
Compared with low dose CsA versus standard dose CsA, Cordyceps did not demonstrate any statistically significant differences in patient survival, graft loss, acute rejection or allograft function. There was limited low quality evidence to suggest benefits in pulmonary infection, serum albumin, serum uric acid levels, CNI nephrotoxicity and hepatotoxicity.
None of the included studies reported on quality of life, and follow-up was short-term (three months to one year). Given the limited number of small studies, and high risk of bias, results should be interpreted with caution.
作者结论
Although there were some favourable aspects associated with Cordyceps, longer-term studies are needed to clarify any benefit-harm trade-off. Future studies should investigate the use of Cordyceps in combination with other immunosuppressive agents such as tacrolimus, mycophenolate mofetil or induction therapy. Such studies also need to be appropriately sized and powered.
